MedTrace Logo

Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma

NCT00847223 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-08-23

No results posted yet for this study

Summary

To determine the EFFICACY and the SAFETY PROFILE and TOXICITY of Zarnestra® in the treatment of patients with previously treated mantle cell lymphoma not appropriate for autologous bone marrow transplantation. 27 evaluable subjects will be enrolled for an analysis in 2 stages (11 for the first stage, 16 for the second).

Patients who receive at least one dose of Zarnestra® and have at least one post-baseline response assessment of discontinued study frug for early progression are evaluable. Subjects not evaluable for response will be replaced, up to 35 patients.

Conditions

Interventions

DRUG

ZARNESTRA (Tipifarnib)

Sponsors & Collaborators

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • Catherine THIEBLEMONT, MD · Lymphoma Study Association

  • Hervé TILLY, MD · Lymphoma Study Association

  • Catherine SEBBAN, MD · Lymphoma Study Association

  • Bertrand COIFFIER, MD · Lymphoma Study Association

  • Serge BOLOGNA, MD · Lymphoma Study Association

  • Olivier CASASNOVAS, MD · Lymphoma Study Association

  • Richard DELARUE, MD · Lymphoma Study Association

  • Réda BOUABDALLAH, MD · Dr

  • Franck MORSCHHAUSER, MD · Lymphoma Study Association

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-03-31
Completion
2009-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847223 on ClinicalTrials.gov